Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Overview | 10 | 1 |
| Therapeutics Development | 11 | 4 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Products under Development by Stage of Development | 11 | 1 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Products under Development by Therapy Area | 12 | 1 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Products under Development by Indication | 13 | 2 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Pipeline Products Glance | 15 | 2 |
| Late Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Products under Development by Companies | 17 | 4 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Products under Development by Universities/Institutes | 21 | 2 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Therapeutics Assessment | 23 | 7 |
| Assessment by Monotherapy/Combination Products | 23 | 1 |
| Assessment by Mechanism of Action | 24 | 2 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Companies Involved in Therapeutics Development | 30 | 20 |
| Amgen Inc. | 30 | 1 |
| Antisense Therapeutics Limited | 31 | 1 |
| Astellas Pharma Inc. | 32 | 1 |
| AstraZeneca Plc | 33 | 1 |
| Axelar AB | 34 | 1 |
| Boehringer Ingelheim GmbH | 35 | 1 |
| Bristol-Myers Squibb Company | 36 | 1 |
| Eli Lilly and Company | 37 | 1 |
| F. Hoffmann-La Roche Ltd. | 38 | 1 |
| Genmab A/S | 39 | 1 |
| Immunomedics, Inc. | 40 | 1 |
| Insmed Incorporated | 41 | 1 |
| Merck &Co., Inc. | 42 | 1 |
| Merrimack Pharmaceuticals, Inc. | 43 | 1 |
| Novartis AG | 44 | 1 |
| PharmAbcine, Inc. | 45 | 1 |
| ProteoThera, Inc. | 46 | 1 |
| Silver Creek Pharmaceuticals, Inc. | 47 | 1 |
| Sucampo Pharmaceuticals, Inc. | 48 | 1 |
| TyrNovo Ltd. | 49 | 1 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Drug Profiles | 50 | 46 |
| 1R-15-15 Drug Profile | 50 | 1 |
| 1R-3s Drug Profile | 51 | 1 |
| 1R-E1-E1 Drug Profile | 52 | 1 |
| ATL-1101 Drug Profile | 53 | 2 |
| AXL-1717 Drug Profile | 55 | 3 |
| AZD-3463 Drug Profile | 58 | 1 |
| BI-893923 Drug Profile | 59 | 1 |
| BMS-754807 Drug Profile | 60 | 1 |
| CT-707 Drug Profile | 61 | 1 |
| dalotuzumab Drug Profile | 62 | 2 |
| Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis Drug Profile | 64 | 1 |
| ganitumab Drug Profile | 65 | 3 |
| lenaldekar Drug Profile | 68 | 1 |
| linsitinib Drug Profile | 69 | 3 |
| M-590 Drug Profile | 72 | 1 |
| mecasermin rinfabate (recombinant) Drug Profile | 73 | 3 |
| MM-141 Drug Profile | 76 | 2 |
| Monoclonal Antibody to Antagonize IGF-IR and Inhibit VEGF for Oncology Drug Profile | 78 | 1 |
| Monoclonal Antibody to Antagonize IGFR-1 for Oncology and Inflammatory Disorders Drug Profile | 79 | 1 |
| NT-219 Drug Profile | 80 | 1 |
| Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine Drug Profile | 81 | 1 |
| Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis Drug Profile | 82 | 1 |
| Recombinant Protein to Agonize Insulin Like Growth Factor 1 Receptor for Phelan-McDermid Syndrome Drug Profile | 83 | 1 |
| Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer Drug Profile | 84 | 1 |
| Recombinant Proteins to Agonize IGF-1R for Myocardial Infarction Drug Profile | 85 | 1 |
| RU-105 Drug Profile | 86 | 1 |
| Small Molecule to Antagonize IGF-1R for Oncology Drug Profile | 87 | 1 |
| Small Molecules to Inhibit IGF-1R for Oncology Drug Profile | 88 | 1 |
| Small Molecules to Inhibit IGF-1R/IR for Oncology Drug Profile | 89 | 1 |
| teprotumumab Drug Profile | 90 | 2 |
| Vaccine to Target HER-2, IGFBP-2 and IGF1R for Breast Cancer Drug Profile | 92 | 1 |
| vesiculin Drug Profile | 93 | 1 |
| XGFR-2 Drug Profile | 94 | 1 |
| XGFR-4 Drug Profile | 95 | 1 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Dormant Projects | 96 | 7 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Discontinued Products | 103 | 5 |
| Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Featured News &Press Releases | 108 | 11 |
| Jul 29, 2015: CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave s Orbitopathy | 108 | 1 |
| May 05, 2015: Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer | 108 | 1 |
| Apr 21, 2015: First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients | 109 | 1 |
| Mar 17, 2015: Study suggests precision medicine for adrenal cancer | 110 | 1 |
| Jan 20, 2015: Merrimack Pharmaceuticals Presents First-in-human study of MM-141 at the American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium | 111 | 1 |
| Nov 05, 2014: FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals MM-141 for the Treatment of Pancreatic Cancer | 112 | 1 |
| Jun 02, 2014: Merrimack Pharmaceuticals Presents Phase 1 Clinical Data From MM-141 at the 2014 ASCO Annual Meeting | 113 | 1 |
| Feb 18, 2014: Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics | 113 | 1 |
| Jan 14, 2014: AmorChem Invests In A Potential Therapy For Late-Stage Breast Cancer | 114 | 1 |
| Dec 27, 2013: Axelar announces final data from Phase II study with AXL1717 in lung cancer | 115 | 1 |
| Oct 15, 2013: Merrimack Pharmaceuticals to Present Preclinical Data On MM-141 at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | 116 | 1 |
| Jun 11, 2013: Genmab To Restart Clinical Development Of Teprotumumab In Phase II Study For Treatment Of Active Thyroid Eye Disease | 116 | 1 |
| Jun 11, 2013: River Vision Receives US Orphan Drug Designation For RV001 For Treatment Of Graves Orbitopathy | 116 | 1 |
| Apr 02, 2013: Axelar Announces Preliminary Results From Phase II Study Demonstrating Efficacy Of AXL1717 In Non-Small Cell Lung Cancer Patients | 117 | 1 |
| Jan 21, 2013: Axelar Initiates Phase I/II Study Of AXL1717 In Patients With Malignant Astrocytomas In US | 117 | 2 |
| Appendix | 119 | 2 |
| Methodology | 119 | 1 |
| Coverage | 119 | 1 |
| Secondary Research | 119 | 1 |
| Primary Research | 119 | 1 |
| Expert Panel Validation | 119 | 1 |
| Contact Us | 119 | 1 |
| Disclaimer | 120 | 1 |